Claims for Patent: 9,085,618

Summary for Patent: 9,085,618

Title:	Low acidic species compositions and methods for producing and using the same
Abstract:	The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF.alpha. is detrimxental, are also provided.
Inventor(s):	Ramasubramanyan; Natarajan (Westborough, MA), Yang; Lihua (Westborough, MA), Herigstad; Matthew Omon (Charlestown, MA), Yang; Hong (Worchester, MA), Subramanian; Kartik (Northborough, MA), Zeng; Xiaobei (Carolina, PR), Dong; Diane D. (Shrewsbury, MA), Lim; Wen Chung (Worchester, MA), Gifford; Kathreen A. (Marlborough, MA), Kaymakcalan; Zehra (Westborough, MA), Chumsae; Christopher (North Andover, MA)
Assignee:	AbbVie, Inc. (North Chicago, IL)
Application Number:	14/077,871
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,085,618
Patent Claims:	1. A low acidic species composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab and wherein less than 75% of the lysine variant species of the composition have zero C-terminal lysines (Lys 0), and wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm. 2. The composition of claim 1, wherein the acidic species of adalimumab comprise a first acidic region (AR1) and a second acidic region (AR2). 3. The composition of claim 1, wherein the adalimumab is produced in a mammalian host cell grown in cell culture. 4. The composition of claim 3, wherein the mammalian host cell is selected from the group consisting of a CHO cell, an NSO cell, a COS cell, and an SP2 cell. 5. The composition of claim 3, wherein the composition comprises 9% or less acidic species of adalimumab. 6. The composition of claim 3, wherein the composition comprises 1.4% to 9% acidic species of adalimumab. 7. The composition of claim 3, wherein the composition comprises 8% or less acidic species of adalimumab. 8. The composition of claim 3, wherein the composition comprises 7% or less acidic species of adalimumab. 9. A pharmaceutical composition suitable for administration to a subject comprising the composition of claim 3 and a pharmaceutically acceptable carrier. 10. The pharmaceutical composition of claim 9, wherein adalimumab is present in the pharmaceutical composition at a concentration of 25-100 mg/ml. 11. The pharmaceutical composition of claim 9, wherein the pH of the pharmaceutical composition is between 5.0 to 6.5. 12. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition comprises one or more excipient. 13. The pharmaceutical composition of claim 12, wherein the one or more excipient is selected from the group consisting of a buffering agent, a surfactant and a polyol, or a combination thereof. 14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises the surfactant polysorbate 80. 15. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises an amino acid buffering agent. 16. The pharmaceutical composition of claim 15, wherein the amino acid is histidine. 17. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises the polyol mannitol. 18. A low acidic species composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab and wherein less than 75% of the lysine variant species of the composition have zero C-terminal lysines (Lys 0), wherein the acidic species of adalimumab have a net negative charge relative to the adalimumab main species and the acidic species comprise species selected from the group consisting of charge variants, structure variants, fragmentation variants and any combinations thereof; and wherein the acidic species of adalimumab do not include process-related impurities selected from the group consisting of host cell proteins, host cell nucleic acids, chromatographic materials and media components. 19. The composition of claim 18, wherein the charge variants comprise one or more of deamidation variants, glycation variants, afucosylation variants, MGO variants or citric acid variants, the structure variants comprise one or more of glycosylation variants or acetonation variants, and the fragmentation variants comprise one or more of Fab fragment variants, C-terminal truncation variants or variants missing a heavy chain variable domain. 20. The composition of claim 18, wherein the % acidic species is determined using WCX-10 HPLC wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm, and wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab. 21. The composition of claim 18, wherein the adalimumab is produced in a mammalian host cell grown in cell culture. 22. The composition of claim 21, wherein the composition comprises 8% or less acidic species of adalimumab. 23. A pharmaceutical composition suitable for administration to a subject comprising the composition of claim 21 and a pharmaceutically acceptable carrier. 24. The pharmaceutical composition of claim 23, wherein the pharmaceutical composition comprises one or more excipient selected from the group consisting of a buffering agent, a surfactant and a polyol, or a combination thereof. 25. A pharmaceutical composition suitable for administration to a subject comprising 25-100 mg of a low acidic species adalimumab composition, wherein the low acidic species adalimumab composition comprises less than 10% total acidic species of adalimumab and wherein less than 75% of the lysine variant species of the composition have zero C-terminal lysines (Lys 0), and wherein the acidic species of adalimumab are quantified based on the relative area percent of peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5) and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm; and a buffering agent, wherein the pH of the pharmaceutical composition is between 5.0 to 6.5. 26. The pharmaceutical composition of claim 25, wherein the low acidic species adalimumab composition comprises 1.4 to 9% acidic species of adalimumab. 27. The pharmaceutical composition of claim 25, wherein the low acidic species adalimumab composition comprises 8% or less acidic species of adalimumab. 28. A method for treating a subject having a disorder in which TNF.alpha. is detrimental, comprising administering to the subject the pharmaceutical composition of claim 9, thereby treating the subject having a disorder in which TNF.alpha. is detrimental. 29. The method of claim 28, wherein the disorder in which TNF.alpha. is detrimental is selected from the group consisting of: rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's Disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), uveitis, active axial spondyloarthritis (active axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA). 30. A method for treating a subject having a disorder in which TNF.alpha. is detrimental, comprising administering to the subject the pharmaceutical composition of claim 25, thereby treating the subject having a disorder in which TNF.alpha. is detrimental.

Details for Patent 9,085,618

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2033-10-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2033-10-18